• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Akero Therapeutics Inc (NQ: AKRO )

    34.45 -0.42 (-1.20%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 811,496
    Open 34.73
    Bid (Size) 32.85 (5)
    Ask (Size) 36.32 (5)
    Prev. Close 34.87
    Today's Range 33.35 - 34.73
    52wk Range 13.39 - 37.00
    Shares Outstanding 50,086,978
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Akero Therapeutics Inc.
    Via GlobeNewswire
    Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
    From Akero Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    +46.72%
    +46.72%
    1 Month
    +18.47%
    +18.47%
    3 Month
    +42.41%
    +42.41%
    6 Month
    +67.07%
    +67.07%
    1 Year
    +143.29%
    +143.29%

    More News

    Read More
    Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
    From Akero Therapeutics Inc.
    Via GlobeNewswire
    AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
    From Akero Therapeutics Inc.
    Via GlobeNewswire
    Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Akero Therapeutics Inc.
    Via GlobeNewswire
    AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
    From Kahn Swick & Foti, LLC
    Via Business Wire
    AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Akero Therapeutics Inc.
    Via GlobeNewswire
    This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
    Via Benzinga
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    AKERO THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.